ArticleThe New England journal of medicine2020
Reconsidering the Trade-offs of Prostate Cancer Screening.
Abstract read
In one paragraph
Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of PSA reference intervals in the gender diverse population with prostates.BJU international · 2025Pooled it
- Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).European radiology · 2024Trial
- Evaluation of a Methylated Circulating Tumour DNA Panel for Detection and Disease Stratification in Prostate Cancer.International journal of molecular sciences · 2026Article
- A guide to cancer screening.Nature reviews. Clinical oncology · 2026Review
- Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.Nature cancer · 2026Article
- Prostate Cancer: Etiology, Diagnosis, and Treatment.Serican journal of medicine · 2026Article
- Methylation-specific, universal, and highly sensitive identification of ctDNA in prostate cancer by multiplex droplet digital PCR.PloS one · 2026Article
- Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes.Current oncology (Toronto, Ont.) · 2025Article
- Prostate cancer screening.Asian journal of urology · 2025Review
- Patient and Physician Perceptions of Prostate-Specific Antigen Testing Among Black Individuals.JAMA network open · 2025Article
- Prostate Cancer Mortality Trend in Montenegro 1990-2018.Iranian journal of public health · 2025Article
- Understanding Barriers to Engagement With a Prostate Cancer Research and Genetic Risk Service Among UK Men of Black African or Black Caribbean Ancestry.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Facilitators of, and barriers to, prostate cancer screening uptake: A descriptive phenomenological study of adult men in Namibia.BMC urology · 2025Article
- Does inclusion of neighborhood variables improve clinical risk prediction for advanced prostate cancer in Black and White men?Urologic oncology · 2025Article
- Metformin in overcoming enzalutamide resistance in castration-resistant prostate cancer.The Journal of pharmacology and experimental therapeutics · 2025Article
- Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database.Urologic oncology · 2024Article
- Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.Journal of the National Cancer Institute · 2024Article
- Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study.Translational andrology and urology · 2024Article
- Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era.Scientific reports · 2024Article
- The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics-Real-world Evidence from 2018 to 2022.European urology open science · 2024Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Jonathan E ShoagFrom the Department of Urology, Weill Cornell Medicine, New York (J.E.S., J.C.H.); and the Department of Urology, University of Washington (Y.A.N.), and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (Y.A.N., R.G., R.E.) - both in Seattle.
Yaw A NyameFrom the Department of Urology, Weill Cornell Medicine, New York (J.E.S., J.C.H.); and the Department of Urology, University of Washington (Y.A.N.), and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (Y.A.N., R.G., R.E.) - both in Seattle.
Roman GulatiFrom the Department of Urology, Weill Cornell Medicine, New York (J.E.S., J.C.H.); and the Department of Urology, University of Washington (Y.A.N.), and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (Y.A.N., R.G., R.E.) - both in Seattle.ORCID 0000-0002-7592-6567
Ruth EtzioniFrom the Department of Urology, Weill Cornell Medicine, New York (J.E.S., J.C.H.); and the Department of Urology, University of Washington (Y.A.N.), and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (Y.A.N., R.G., R.E.) - both in Seattle.ORCID 0000-0002-9164-6370
Jim C HuFrom the Department of Urology, Weill Cornell Medicine, New York (J.E.S., J.C.H.); and the Department of Urology, University of Washington (Y.A.N.), and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (Y.A.N., R.G., R.E.) - both in Seattle.
Funding
Modeling to Improve Prostate Cancer Outcomes Across Diverse PopulationsU01CA199338 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DE KONING, HARRY J, ETZIONI, RUTH D · 2015 to 2019
$5.2MStatistical modeling to support population and translational cancer researchR50CA221836 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Roman Gulati · 2017 to 2026
$2.0MNCI NIH HHS R50 CA221836NCI NIH HHS U01 CA199338
Abstract
PubMed holds no abstract for this paper.
Indexed as
Early Detection of CancerFollow-Up StudiesHumansMalePostoperative ComplicationsProstate-Specific AntigenProstatic NeoplasmsRandomized Controlled Trials as TopicProstate-Specific Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.